Yu, Chia-Ling, Liang, Chih-Sung ORCID: https://orcid.org/0000-0003-1138-5586, Yang, Fu-Chi ORCID: https://orcid.org/0000-0001-6831-3634, Tu, Yu-Kang ORCID: https://orcid.org/0000-0002-2461-474X, Hsu, Chih-Wei ORCID: https://orcid.org/0000-0002-8650-4060, Carvalho, Andre F., Stubbs, Brendon, Thompson, Trevor ORCID: https://orcid.org/0000-0001-9880-782X, Tsai, Chia-Kuang ORCID: https://orcid.org/0000-0001-7693-1408, Yeh, Ta-Chuan, Yang, Szu-Nian, Shin, Jae Il ORCID: https://orcid.org/0000-0003-2326-1820, Chu, Che-Sheng ORCID: https://orcid.org/0000-0002-6911-1839, Tseng, Ping-Tao ORCID: https://orcid.org/0000-0001-5761-7800 and Su, Kuan-Pin (2022) Trajectory of antidepressant effects after single- or two-dose administration of psilocybin: a systematic review and multivariate meta-analysis. Journal of Clinical Medicine, 11 (4):938. ISSN 2077-0383 (Online) (doi:10.3390/jcm11040938)

Preview

PDF (Publisher VoR) 35183_THOMPSON_Trajectory_of antidepressant_effects.pdf - Published Version Available under License Creative Commons Attribution. Download (6MB) | Preview

Abstract

We examined the cardiovascular safety, acceptability, and trajectory of the antidepressant effects of psilocybin after single- or two-dose administration. Four major electronic databases were systematically searched. Data were pooled using a multivariate random-effects meta-analysis. Primary outcomes were changes in depressive symptoms. Secondary outcomes were cardiovascular safety and acceptability. Ten studies were included. The estimated effect sizes (standardized mean difference (SMD) with 95% confidence intervals) for psilocybin were −0.75 (−1.15 to −0.35) on day 1, −1.74 (−2.15 to −1.32) at 1 week, −1.35 (−1.77 to −0.93) at 1 month, −0.91 (−1.31 to −0.51) at 3 months, and −1.12 (−1.56 to −0.68) at 6 months. Higher doses and two sessions of psilocybin treatment were significantly associated with superior antidepressant effects. The all-cause discontinuation and heart rate after psilocybin administration were comparable to placebo; meanwhile, psilocybin increased systolic and diastolic blood pressure by 19.00 mmHg and 8.66 mmHg, respectively. There were no significant differences between SMD derived from placebo-controlled trials compared to those from pre–post changes and SMD in randomized controlled trials (RCTs) compared to those in non-RCTs. The present study demonstrates that single- or two-dose psilocybin administration has rapid and sustained antidepressant effects for up to 6 months, with favorable cardiovascular safety and acceptability

Item Type:	Article
Additional Information:	Included in Special Issue "Depressive Disorders—Common Pathomechanisms of Somatic and Psychiatric Comorbidity."
Uncontrolled Keywords:	depression; meta-analysis; psilocybin; psychedelics
Subjects:	B Philosophy. Psychology. Religion > BF Psychology R Medicine > RS Pharmacy and materia medica
Faculty / School / Research Centre / Research Group:	Faculty of Education, Health & Human Sciences Faculty of Education, Health & Human Sciences > Institute for Lifecourse Development Faculty of Education, Health & Human Sciences > Institute for Lifecourse Development > Centre for Chronic Illness and Ageing Faculty of Education, Health & Human Sciences > School of Human Sciences (HUM)
Related URLs:	Publisher
Last Modified:	15 Feb 2022 12:19
URI:	http://gala.gre.ac.uk/id/eprint/35183

Actions (login required)

View Item

Downloads